(Q37753343)

22 August 2017

1 reference

title

Role of new treatment approaches in defining treatment goals in multiple myeloma--the ultimate goal is extended survival (English)

1 reference

22 August 2017

1

Brian G M Durie

1 reference

22 August 2017

publication date

1 May 2010

1 reference

22 August 2017

published in

Cancer Treatment Reviews

1 reference

22 August 2017

volume

36 Suppl 2

1 reference

22 August 2017

page(s)

S18-23

1 reference

Endpoints for assessing drug activity in clinical trials

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Treatment of myeloma: cure vs control

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Clinical trial design for target-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

The role of complete response in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

The evolution of thalidomide and its IMiD derivatives as anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Proteasome inhibitors in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970008-6

7 January 2021

10.1016/S0305-7372(10)70008-6

Identifiers

DOI

1 reference

22 August 2017

1 reference